Efficacy and Safety

TASCENSO ODT is the same proven fingolimod you might be familiar with.1 It is not a generic.2

Efficacy and Safety

TASCENSO ODT is the same proven fingolimod you might be familiar with.1 It is not a generic.2

TASCENSO ODT is bioequivalent to Gilenya® (fingolimod) capsules, therefore it has the:

  • Same safety
  • Same efficacy
  • Same side effects.3

Not only could the unique formulation of TASCENSO ODT suit you, it also means TASCENSO ODT cannot be substituted by Gilenya® or generic fingolimod at the pharmacy level.

Safety

TASCENSO ODT may cause serious side effects, including:

  • Slow heart rate (bradycardia or bradyarrhythmia) when you start taking TASCENSO ODT.
  • Swelling and narrowing of the blood vessels in your brain.
  • Harm to an unborn baby if you are pregnant.
  • An increase risk of infections.
  • Progressive multifocal leukoencephalopathy (PML).
  • Immune reconstitution inflammatory syndrome (IRIS).
  • A problem with your vision.
  • Liver damage.
  • Breathing problems.
  • Severe worsening of multiple sclerosis after stopping TASCENSO ODT.
  • Increased blood pressure.
  • Types of skin cancer.
  • Allergic reactions.

Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

The most common side effects of TASCENSO ODT include:

  • headache
  • abnormal liver tests
  • diarrhea
  • cough
  • flu
  • inflammation of the sinuses (sinusitis)
  • back pain
  • stomach-area (abdominal) pain
  • pain in arms or legs

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all of the possible side effects of TASCENSO ODT.

For more information, ask your healthcare provider or pharmacist. Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Read more about TASCENSO ODT
Get started with TASCENSO ODT

Gilenya® is a registered trademark of Novartis AG.

References

1. TASCENSO ODT (fingolimod). Prescribing Information. Cycle Pharmaceuticals Ltd.
2. FDA., 2022. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Accessed January 3rd 2023. Available: www.accessdata.fda.gov/scripts/cder/ob/index.cfm
3. Data on file: REF-00069.